Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination represents the control arm used in Phase 3 clinical trials for treatment-naive severe aplastic anemia (SAA), specifically those sponsored by Jiangsu HengRui Medicine Co., Ltd. evaluating hetrombopag. The standard therapy component consists of a regimen of immunosuppressive therapy (IST) including antithymocyte globulin (ATG) and cyclosporine. ATG is a polyclonal antibody that induces T-cell depletion, while cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and cytokine production. This combination is the established standard of care for SAA patients who are ineligible for bone marrow transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + antithymocyte globulin + cyclosporine.